NCT02872116: A reported trial by Bristol-Myers Squibb
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02872116 |
|---|---|
| Title | A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 12, 2016 |
| Completion date | May 27, 2020 |
| Required reporting date | May 27, 2023, midnight |
| Actual reporting date | May 18, 2022 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |